Navigation Links
MultiCell Technologies Signs Worldwide Exclusive License Agreement With Corning Incorporated
Date:10/10/2007

rmaceutical company committed to the development of new drug candidates and whose current drug candidates include:

-- MCT-125 for the treatment of primary fatigue in MS patients.

-- MCT-175 for the treatment of relapsing-remitting MS.

-- MCT-465 for the treatment of TLR3 positive breast cancers.

-- MCT-475 for the treatment of TLR3 positive cervical cancers.

For more information about MultiCell Technologies, please visit http://www.multicelltech.com

Caution Regarding Forward-Looking Statements

Any statements in this press release about MultiCell's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). These statements are often, but not always, made through the use of words or phrases such as "believe," "will," "expect," "anticipate," "estimate," "intend," "plan," "forecast," "could," and "would." Examples of such forward looking statements include statements regarding the timing, design, scope, and anticipated results of our clinical development of MCT-125, statements regarding selling, using or developing the FA2N-4 cell line and MultiCell's identification of new drug targets. MultiCell bases these forward-looking statements on current expectations about future events. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections in the forward-looking statement include, but are not limited to, the risk that we might not achieve our anticipated clinical development milestones, receive regulatory
'/>"/>

SOURCE MultiCell Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Barriers will not stop convergence of medical technologies
2. Merge Technologies net loss doubles to $10.1M
3. Making deals with evolving technologies in mind
4. Third Wave Technologies to raise $14.9M through private debt
5. Meier joins Broadlook Technologies as COO
6. Platypus Technologies secures $450K SBIR grant
7. Napier joins board of Third Wave Technologies
8. aOva Technologies raises $3 million
9. Consumer, business technologies face same challenges
10. Promega to get early access to WARF technologies under new agreement
11. Linda Weber to run Fiservs Interactive Technologies unit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Oncothyreon Inc. (NASDAQ: ONTY ) today announced ... offerings of 10,000,000 shares of its Common Stock at ... for expected gross proceeds of $20 million and 10,000 ... a price to the public of $2,000.00 per share, ... of Series A Convertible Preferred Stock is non-voting and ...
(Date:9/18/2014)... OMICS Group International invites researchers, authors ... the ‘Open Access Week’ by actively contributing their ... Pharma Journals from 20-26th October, 2014. , ... Sciences, accelerating with a tremendous speed to provide ... The industry is gearing with innovation and technological ...
(Date:9/18/2014)... expensive. Now a team led by an engineer at ... designs that will let scientists slash the cost of ... , Syringe pumps are used to dispatch precise amounts ... in a reaction. They can also cost hundreds or ... team of Michigan Tech students published the library of ...
(Date:9/18/2014)... touch in the course of a day - ... rely on the chemical industry to turn raw ... products into valuable chemicals that are the ingredients ... Sarina Sarina, who achieved outstanding progress in driving ... temperature using light instead of fossil fuels, has ...
Breaking Biology Technology:Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3Pharma and Omics Journals to Address Global Challenges during Open Access Week 2Pharma and Omics Journals to Address Global Challenges during Open Access Week 3Doing science just got cheaper -- and faster 2Using solar energy to turn raw materials into ingredients for every day life 2
... Sponsors 2010 Semantic Web Challenge -- NEW YORK, November 16, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... = function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we need to ...
... London, involves a new class of materials called metamaterials, ... sound waves. With conventional materials, light typically travels along ... a wealth of additional flexibility to create undetectable blind ... an image can be altered or made to look ...
... 15, 2010, PRNewswire-Asia/ -- Tiens Biotech Group (USA), Inc. (the "Company" ... , today announced financial results for ... Revenue for the third quarter of 2010 was $10.4 million, ... for the nine months ended September 30, 2010 was $30.0 million, ...
Cached Biology Technology:Elsevier Sponsors 2010 Semantic Web Challenge 2Elsevier Sponsors 2010 Semantic Web Challenge 3Elsevier Sponsors 2010 Semantic Web Challenge 4Elsevier Sponsors 2010 Semantic Web Challenge 5Elsevier Sponsors 2010 Semantic Web Challenge 6Elsevier Sponsors 2010 Semantic Web Challenge 7Elsevier Sponsors 2010 Semantic Web Challenge 8Elsevier Sponsors 2010 Semantic Web Challenge 9Elsevier Sponsors 2010 Semantic Web Challenge 10Elsevier Sponsors 2010 Semantic Web Challenge 11'Space-time cloak' to conceal events revealed in new study 2'Space-time cloak' to conceal events revealed in new study 3Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results 2Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results 3Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results 4Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results 5Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results 6Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results 7Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results 8Tiens Biotech Group (USA) Reports Third Quarter and Nine-Month Results 9
(Date:9/19/2014)... it the Jimmy Durante of dinosaurs a ... profile. The new dinosaur, named Rhinorex condrupus ... and Brigham Young University, lived in what is ... the Late Cretaceous period. , Rhinorex, which translates ... a close relative of other Cretaceous hadrosaurs like ...
(Date:9/19/2014)... A new resource unveiled today by researchers from ... College Dublin provides both experienced and aspiring researchers ... build, and operate robots made from soft, flexible ... printing, laser cutters, and other advances in manufacturing ... important field. Using principles drawn from conventional rigid ...
(Date:9/19/2014)... A University of Oklahoma biology professor will study the ... analysis that could eventually benefit people,s health. The ... manage the energy required to produce the signals used ... generate electric signals at a rate of 500-600 discharges ... required for the electric fish are extreme, but necessary ...
Breaking Biology News(10 mins):New hadrosaur noses into spotlight 2Soft robotics 'toolkit' features everything a robot-maker needs 2
... Researchers have discovered a potentially important new resistance factor ... team of researchers from Canadian Blood Services, The Hospital ... Sweden have discovered that certain blood types are more ... at fending it off. A carbohydrate-containing antigen, termed ...
... of painstakingly handwritten books produced in medieval Europe still ... about when and where the majority of these works ... is using modern advances in genetics to develop techniques ... important cultural artifacts. Many medieval manuscripts were written ...
... new technologies that make it easier to sequence the ... Cancer Center have identified a series of genes that ... other. These recurrent gene fusions are thought to be ... The gene fusions discovered could potentially serve as ...
Cached Biology News:Researchers identify potential new weapon in battle against HIV infection 2DNA testing may unlock secrets of medieval manuscripts 2U-M researchers discover new genes that fuse in cancer 2
"BioTracker 6X Bromophenol Blue Tracking Dye is composed of 60% St DI H2O, 30% Glycerol, 10% 10XTE, 0.25% BPB Dye and 0.85% SDS....
Request Info...
Request Info...
Request Info...
Biology Products: